
    
      Official Study Title: Phase I, open label, two period, study to evaluate the effects of
      fosamprenavir/ritonavir on GSK1349572 pharmacokinetics and a phase I, randomized, three-way
      crossover study to evaluate the relative bioavailability of three tablet variants made using
      micronized, unmicronized and intermediate particle sizes of GSK1349572 in healthy adult
      subjects (ING113068).

      ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of
      updating systems to reflect the change in sponsorship
    
  